A HIGH-TECH medicine manufacturer is set to create 50 new jobs while safeguarding more than 130 existing positions with the purchase of new premises in Stirling.
Symbiosis Pharmaceutical Services Ltd (Symbiosis), has recently announced the purchase of new premises, the Bruce Building in Castle Business Park.
The building is located close to Symbiosis’ existing manufacturing cleanrooms, testing laboratories and GMP Warehouse facilities. The new manufacturing capacity is hoped to safeguard more than 130 skilled life sciences jobs at Symbiosis and generate an additional 50 new jobs
The facility fit-out project will be implemented over a three-year period with financial support provided by Barclays Bank for the purchase of the building.
The new manufacturing facility also includes plans for two new cleanroom-based production lines with the aim to strengthen the company's ability to support its biotechnology and pharmaceutical clients worldwide and the new medicines and therapies being developed.
Symbiosis CEO Colin MacKay commented: “By investing £1.75m ($2.25m) in the purchase of a 20,000sq/ft building and subsequently equipping it to provide additional world-class sterile manufacturing capacity for our existing and future clients globally represents the next major strategic chapter in the successful and consistently fast-growing trajectory of Symbiosis.
“This step-change in operational capacity, while retaining the organisational and cultural strengths of a fantastic team here at Symbiosis, positions the company for sustained growth and to bring continued added value to both clients and shareholders alike."
Retiring Stirling Council Leader, councillor Chris Kane welcomed the "absolutely fantastic news for Stirling, the wider region and Scotland".
He added: “Symbiosis’ significant investment at their site will safeguard and create skilled jobs in Stirling’s thriving life sciences and manufacturing sector. It’s an endorsement of Stirling’s world-class talent, research skills and innovation, and our location at the heart of one of Europe’s largest and most well-connected biotech clusters.
“The announcement reaffirms Stirling’s reputation as a place for attracting and retaining businesses, and we look forward to working with high-growth, internationally-acclaimed businesses like Symbiosis to continue developing this key sector.”
